Evidence map›Paper›PMID 29845115›Full record

ArticleNeurology. Genetics2018

Brain copper storage after genetic long-term correction in a mouse model of Wilson disease.

Ricarda Uerlings, Daniel Moreno, Oihana Murillo, Cristina Gazquez, Rubén Hernández-Alcoceba, Gloria González-Aseguinolaza, Ralf Weiskirchen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Wilson disease-treatment perspectives.Annals of translational medicine · 2019
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ricarda UerlingsInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain.
Daniel MorenoInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain.
Oihana MurilloInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain.
Cristina GazquezInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain.
Rubén Hernández-AlcocebaInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain.
Gloria González-AseguinolazaInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain.
Ralf WeiskirchenInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (R.U., R.W.), RWTH University Hospital Aachen, Aachen, Germany; Gene Therapy and Regulation of Gene Expression Program (D.M., O.M., C.G., R.H.-A., G.G.-A.), CIMA, Foundation for Applied Medical Research, University of Navarra; Instituto de Investigacion Sanitaria de Navarra (IDISNA) (D.M., O.M., C.G., R.H-.A., G.G.-A.); and Vivet-Therapeutics (G.G.-A.), Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID29845115
PMCPMC5961192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.